Intellia Therapeutics
NTLA
280 hedge funds and large institutions have $934M invested in Intellia Therapeutics in 2025 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 111 increasing their positions, 87 reducing their positions, and 53 closing their positions.
63% more call options, than puts
Call options by funds: $18.2M | Put options by funds: $11.2M
30% more capital invested
Capital invested by funds: $720M → $934M (+$213M)
28% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 87
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.75% less ownership
Funds ownership: 97.84% → 96.1% (-1.7%)
5% less funds holding
Funds holding: 294 → 280 (-14)
21% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 53
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$16.7M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$9.81M |
| 3 |
D.E. Shaw & Co
New York
|
+$6.51M |
| 4 |
Renaissance Technologies
New York
|
+$5.56M |
| 5 |
MG
Marex Group
London,
|
+$5.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$26.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$16.8M |
| 3 |
CC
Casdin Capital
New York
|
-$14.2M |
| 4 |
BlackRock
New York
|
-$4.34M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$4.24M |
NTLA Hedge Fund Activity: Q2 2025 in Review
280 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q2 2025, worth a combined $934M — up 30% from $720M a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of NTLA and 42 opened new positions — a net loss of 11 holders — while 87 trimmed existing stakes and 111 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $16.7M. The largest seller was Capital International Investors, exiting entirely with an estimated $26.9M sold.
- 280 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2025, down from 294 in Q1 2025.
- Funds reported $934M of Intellia Therapeutics stock for Q2 2025, up 30% quarter-over-quarter.
- 42 funds opened new Intellia Therapeutics positions in Q2 2025 and 53 closed out, a net change of -11 holders.
- The largest Intellia Therapeutics buyer in Q2 2025 was Baker Bros. Advisors, an estimated $16.7M added.
- The largest Intellia Therapeutics seller in Q2 2025 was Capital International Investors, an estimated $26.9M sold.
Based on aggregated 13F filings for Q2 2025.